牛牛AI助手已提取核心信息
SciSparc Ltd., a company listed in the United States, has received notification from the Division of Corporation Finance Office of Life Sciences, part of the United States Securities and Exchange Commission (SEC), that the review of its Form 20-F for the year ended December 31, 2022, has been completed. The communication, addressed to Oz Adler, the CEO and CFO of SciSparc, dated January 18, 2024, also reminds the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review outcome.
SciSparc Ltd., a company listed in the United States, has received notification from the Division of Corporation Finance Office of Life Sciences, part of the United States Securities and Exchange Commission (SEC), that the review of its Form 20-F for the year ended December 31, 2022, has been completed. The communication, addressed to Oz Adler, the CEO and CFO of SciSparc, dated January 18, 2024, also reminds the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review outcome.
在美国上市的公司ScisPARC Ltd. 已收到美国证券交易委员会（SEC）下属的生命科学公司财务处的通知，对截至2022年12月31日止年度的20-F表格的审查已经完成。这封日期为2024年1月18日致ScisPARC首席执行官兼首席财务官奥兹·阿德勒的信函还提醒该公司及其管理层，无论美国证券交易委员会的审查结果如何，他们都对披露的准确性和充分性负责。
在美国上市的公司ScisPARC Ltd. 已收到美国证券交易委员会（SEC）下属的生命科学公司财务处的通知，对截至2022年12月31日止年度的20-F表格的审查已经完成。这封日期为2024年1月18日致ScisPARC首席执行官兼首席财务官奥兹·阿德勒的信函还提醒该公司及其管理层，无论美国证券交易委员会的审查结果如何，他们都对披露的准确性和充分性负责。
有用
没用